Upstream Bio has sailed to a phase 2 win in sinusitis. Yet, in a field heavy with big-name rivals, the results failed to persuade investors that the biotech can swim against the competitive current.

Upstream Bio shares rose after the biotechnology company reported positive results for a trial of a sinus-disease treatment. The stock advanced 7.1% to $18.34 on Tuesday. Shares have gained 12% this ...

Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...

Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining ...

– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...